Hospira Told To Clean Up Manufacturing Process In India

Law360, New York (May 30, 2013, 1:11 PM EDT) -- Hospira Inc. is under fire from the U.S. Food and Drug Administration over allegedly unsanitary conditions at its pharmaceutical manufacturing facility in India that raise concerns about drug contamination, the company said in a regulatory filing Wednesday.

The FDA sent Hospira a warning letter informing the drugmaker of major violations of manufacturing regulations, including failing to properly clean surfaces and using damaged gloves when handling sterile products. The agency said it was particularly concerned because it witnessed similar violations during a recent inspection at Hospira's Rocky...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.